Azitra (AZTR) Accumulated Expenses (2022 - 2026)
Azitra's (AZTR) quarterly Accumulated Expenses came in at $270511.0 in Q1 2026, down 42.12% YoY from $467394.0 in Q1 2025, and up 36.98% on a QoQ basis from $197484.0 in Q4 2025.
Azitra (AZTR) Accumulated Expenses (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Accumulated Expenses data on file, last reported at $270511.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 42.12% year-over-year to $270511.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $270511.0 (down 42.12% YoY) and the FY2025 annual result came in at $197484.0, down 67.24% from the prior year.
- Accumulated Expenses improved to $270511.0 in Q1 2026, from $197484.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $602787.0 in Q4 2024 to a low of $197484.0 in Q4 2025.
- A 5-year average of $410592.0 and a median of $434103.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses soared 78.41% — and 2025, when it slumped 67.24%.
- Tracing AZTR's Accumulated Expenses over 5 years: stood at $371010.0 in 2022, then rose by 3.41% to $383668.0 in 2023, then jumped by 57.11% to $602787.0 in 2024, then tumbled by 67.24% to $197484.0 in 2025, then soared by 36.98% to $270511.0 in 2026.
- The last three Accumulated Expenses figures came in at $270511.0 (Q1 2026), $197484.0 (Q4 2025), and $507329.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 673,669.00 |
| Mar 31, 2026 | 270,511.00 |
| Dec 31, 2025 | 197,484.00 |
| Sep 30, 2025 | 507,329.00 |
| Jun 30, 2025 | 513,166.00 |
| Mar 31, 2025 | 467,394.00 |
| Dec 31, 2024 | 602,787.00 |
| Sep 30, 2024 | 486,981.00 |
| Jun 30, 2024 | 434,103.00 |
| Mar 31, 2024 | 348,930.00 |
| Dec 31, 2023 | 383,668.00 |
| Sep 30, 2023 | 272,950.00 |
| Jun 30, 2023 | 481,383.00 |
| Dec 31, 2022 | 371,010.00 |